These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26826416)

  • 61. [The clinical and pathological features, biomarker characteristics and prognosis analysis of lung adenosquamous carcinoma].
    Zhou SY; Xue Q; Ying JM; Hu XS; Yang JL; Lin H; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2019 Jan; 41(1):50-55. PubMed ID: 30678417
    [No Abstract]   [Full Text] [Related]  

  • 62. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
    Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
    Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
    [TBL] [Abstract][Full Text] [Related]  

  • 63. EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.
    Forest F; Stachowicz ML; Casteillo F; Karpathiou G; Gouzy-Grosjean F; Guilaubey C; Cottier M; Beal J; Clemenson A; Péoc'h M
    Exp Mol Pathol; 2017 Dec; 103(3):306-310. PubMed ID: 29175303
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Strategy for molecular testing in pulmonary carcinoma].
    Penault-Llorca F; Tixier L; Perrot L; Cayre A
    Ann Pathol; 2016 Jan; 36(1):73-9. PubMed ID: 26778816
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
    Yeung SF; Tong JHM; Law PPW; Chung LY; Lung RWM; Tong CYK; Chow C; Chan AWH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2015 Sep; 10(9):1292-1300. PubMed ID: 26098749
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
    Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
    J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients.
    Russell PA; Rogers TM; Solomon B; Alam N; Barnett SA; Rathi V; Williams RA; Wright GM; Conron M
    Pathology; 2017 Oct; 49(6):604-610. PubMed ID: 28811082
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeted sequencing identifies the mutational signature of double primary and metastatic malignancies: a case report.
    Rao C; Nie L; Miao X; Lizaso A; Zhao G
    Diagn Pathol; 2019 Sep; 14(1):101. PubMed ID: 31484545
    [TBL] [Abstract][Full Text] [Related]  

  • 69. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.
    Jia XL; Chen G
    Lung Cancer; 2011 Dec; 74(3):396-400. PubMed ID: 21592614
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung.
    Shiozawa T; Ishii G; Goto K; Nagai K; Mimaki S; Ono S; Niho S; Fujii S; Ohe Y; Tsuchihara K; Ochiai A
    Pathol Int; 2013 Feb; 63(2):77-84. PubMed ID: 23464964
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
    Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Present and future molecular testing of lung carcinoma.
    Dacic S; Nikiforova MN
    Adv Anat Pathol; 2014 Mar; 21(2):94-9. PubMed ID: 24508692
    [TBL] [Abstract][Full Text] [Related]  

  • 73. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
    Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
    Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer.
    Ilie M; Beaulande M; Hamila M; Erb G; Hofman V; Hofman P
    Lung Cancer; 2018 Oct; 124():90-94. PubMed ID: 30268486
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Pathological study of the pleomorphic carcinoma of the lung].
    Xu X; Yin H; Meng K; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2000 Dec; 29(6):424-7. PubMed ID: 11866944
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Squamous cell carcinoma of lung associated with osteoclast-like giant cells: report of a case.
    Kong L; Peng W; Liu J; Wang W; Gong P; Yu G; Li J
    Int J Clin Exp Pathol; 2015; 8(9):11823-5. PubMed ID: 26617934
    [TBL] [Abstract][Full Text] [Related]  

  • 77. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
    Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.
    Tomizawa K; Suda K; Onozato R; Kosaka T; Endoh H; Sekido Y; Shigematsu H; Kuwano H; Yatabe Y; Mitsudomi T
    Lung Cancer; 2011 Oct; 74(1):139-44. PubMed ID: 21353324
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pseudosquamous Adenocarcinoma of the Lung: Clinicopathologic and Immunohistochemical Study of 10 Cases.
    Suster DI; Ronen N; Suster S
    Am J Surg Pathol; 2024 Jul; 48(7):901-908. PubMed ID: 38764378
    [TBL] [Abstract][Full Text] [Related]  

  • 80. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.